Slides
Page 1
Nasdaq:ARTL Pioneering the Science of Lipid Signaling Modulation to Develop Novel Therapeutics January 2026 Corporate Presentation
Page 2
NASDAQ: ARTLNasdaq:ARTL Artelo Biosciences, Inc. (the “Company”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, ESG performance, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in the Company’s business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; disruption to the Company’s operations, including clinical trial delays; the success of any of the Company’s clinical trials and preclinical studies for its product candidates; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval and/or future commercialization; the Company’s ability to obtain and maintain intellectual property protection for its product candidates; the Company may use its capital resources sooner than it expects; and other risks described in the Company’s prior communications and the Company’s filings with the Securities and Exchange Commission (the “SEC”). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our products include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reliable, such assumptions have not been verified by any third party. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors that could cause results to differ materially from those expressed in the estimates made by third parties and by us. Trademarks in this presentation are the property of their respective owners and used for informational and education purposes only. Pipeline programs are under investigation and have not been proven to be safe or effective. There is no guarantee any product will be approved or meet any developmental milestones indicated above. The Company’s SEC filings are available at artelobio.com 2 Forward Looking Statements
Page 3
NASDAQ: ARTLNasdaq:ARTL 3 Corporate Highlights NOVEL SCIENCE PORTFOLIO NEAR-TERM CATALYSTS $B BILLION DOLLAR MARKETS PROVEN LEADERSHIP ROBUST PATENT ESTATE Artelo Biosciences is a clinical-stage biopharmaceutical company advancing a broad platform of lipid signaling modulation drug candidates to treat pain, cancer, anxiety, depression, and other conditions
Page 4
NASDAQ: ARTLNasdaq:ARTL DEVELOPMENT PROGRAM PRECLINICAL Phase 1 Phase 2 Phase 3 ORIGINAL DEVELOPER ART27.13 Dual Cannabinoid Receptor Agonist Cancer-Related Anorexia (Weight Loss) ART12.11 CBD:TMP Cocrystal Cancer-Related Cachexia (Muscle Wasting) ART26.12 FABP5 Inhibitor Chemotherapy-Induced Peripheral Neuropathy Generalized Anxiety Disorder Anxiety / Depression Various Cancers (Including Breast & Prostate) 4 Lipid Signaling Modulation Pipeline FABP5=Fatty Acid Binding Protein 5; CBD=Cannabidiol; TMP=Tetramethylpyrazine Psoriasis
Page 5
NASDAQ: ARTLNasdaq:ARTL Multiple value-driving milestones expected over the next 12-18 months 5 Near-term Clinical Catalysts Phase 2 (interim CAReS) ART27.13 Cancer-Anorexia/Weight Loss Phase 1 (multi-dose) ART26.12 Painful Neuropathies Phase 1 ART12.11 Anxiety/Depression Phase 1 (food effect) ART26.12 Painful Neuropathies 2025 2026 Phase 1 (single-dose) ART26.12 Painful Neuropathies Announced June 30, 2025 Announced August 25, 2025 Announced September 3, 2025
Page 6
ART27.13 Dual Cannabinoid Receptor Agonist for Cancer-Related Anorexia and Cachexia
Page 7
Nasdaq:ARTL When you pull a pair of trousers up and they just fall right back down again, it sort of hits home how quickly the weight dropped off. That was scary. “ ” CACS is marked by a loss of appetite and weight loss, along with a reduction in muscle mass and fatty tissues affecting up to 80% of advanced cancer patients* with no FDA-approved treatment Target Indication: Cancer Anorexia Cachexia Syndrome (CACS) Participant in Phase 1 Artelo-sponsored study ART27.13 Addressing a Significant Need 7*https://www.cancer.gov/about-cancer/treatment/research/cachexia
Page 8
NASDAQ: ARTLNasdaq:ARTL ART27.13 Dual Cannabinoid Receptor Agonist • Synthetic, dual CB1/CB2 full agonist • Oral dosing once daily • Peripherally selective to avoid CNS side effects • Leverages a well-established appetite pathway • Dose-dependent increase in body weight evidenced in 3 clinical studies • New chemical entity, a benzimidazole derivative, originally developed by AstraZeneca Source: https://www.ncbi.nlm.nih.gov/pubmed/22249824; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027162/ 8 Fat Tissue Liver Pancreas Muscle • Increases fat cell differentiation • Increases fat storage • Decreases mitochondrial respiration and oxygen consumption • Decreases adiponectin secretion • Reduces alternative macrophage activation • Inhibits thermogenesis in brown adipocytes • Increases fatty acid synthesis • Induces gluconeogenesis • Promotes liver regeneration • Stimulates insulin secretion. • Reduces insulin-stimulated IR autophosphorylation. • Can lead to β-cell death. • Decreases insulin-mediated glucose uptake • Regulation of oxidative activity GI System • Increases sweet sensitivity Oral Cavity • Direct modification of gut-brain signalling • Modulates gastric vagal afferent mechanosensitivity Afferent vagus nerves • Inhibits secretion of the satiation hormone cholecystokinin • Slows GI motility • Promotes western diet preferences Intestines • Decreases gastric secretion and acetylcholine release. • Delays gastric emptying • Enhances ghrelin (a hormone stimulating hunger) release Stomach • Modulates gut bacteria Microbiome The many effects of peripheral CB1 activation in promoting appetite, food storage and weight gain ART27.13
Page 9
NASDAQ: ARTLNasdaq:ARTL Monkey PET Scan with [11C]-ART27.13 Brain: Plasma Ratio = 0.5. Dose responsive weight increases observed at Day 15 in healthy volunteer study with ART27.13 Effect blocked by a CB2 antagonist but not a CB1 antagonist ART27.13 (100 nM) prevents human myotubule degeneration Declined 36% Improved 32% Stable 32% In CAReS Phase 1, 14/22 (64%) of patients had weight stabilization or weight gain observed at day 28 CB2 agonist effects of ART27.13 prevented tumor induced cachexia muscle degeneration in-vitro Data from a Phase 1 healthy volunteer study conducted by AstraZeneca Data from the CAReS Phase 1 study in cancer patients sponsored by Artelo Data from pre-clinical studies conducted by R. Porter at Trinity Biomedical Institute Noone J, Rooney MF, Karavyraki M, Yates A, O’Sullivan SE, Porter RK. Pharmaceuticals. 2023; 16(11):1580 9 ART27.13 Pre-clinical and Phase 1 Clinical Evidence Observed weight gain ART27.13 versus placebo (P=0.0001) Source: Multiple Ascending Dose Phase 1 Study, AstraZeneca, adMare. Data on file. Data presented by Professor Barry J. A. Laird, at the 17th International Conference on Sarcopenia, Cachexia, & Wasting Disorders, December 6-8, 2024 CAReS = Cancer Appetite Recovery Study
Page 10
NASDAQ: ARTLNasdaq:ARTL Establishing safety, optimal dose, and proof-of-concept in cancer patients with anorexia R = Randomization; QOL = Quality of Life • Lean body mass • Weight gain • Activity • Anorexia • QOL • Safety Phase 2 starting dose established 150 μg 250 μg 400 μg 650 μg 12 weeks treatment with ART27.13 (4 weeks each dose) N=30 12 weeks administration with Placebo (4 weeks each dose) N=10 https://www.isrctn.com/ISRCTN15607817 Cancer patients with anorexia N=24 (6 per dose level) Phase 1 (Completed) Phase 2 (Interim data announced) Cancer patients with anorexia N=40 (3:1 randomization) R Evaluating 650 μg 1000 μg 1300 μg ART27.13 The CAReS Trial 10 CAReS = Cancer Appetite Recovery Study
Page 11
NASDAQ: ARTLNasdaq:ARTL Phase 1: 27 patients received at least one dose of ART27.13. No events considered as dose limiting toxicities and no fatal AEs related to trial treatment. The most common (> 1 patient) AEs related to trial drug were somnolence (11%) and dry mouth (11%). All data collected over and up to 12-week dosing period Phase 2: At interim analysis, 25 patients had received at least one dose of ART27.13. Seven (32%) had AEs considered related to study drug compared to 8 (30%) in Phase 1. • There were no SAEs and no fatal AEs related to trial treatment • 4 patients discontinued study drug due to AEs compared to 8 in Phase 1 • The most common (> 2 patients) AEs related to trial drug were vomiting (12%) and dry mouth (12%) • The safety profile observed in Phase 2 is very similar to that observed in Phase 1, despite doses of up to 1300 µg being administered • ART27.13 is well-tolerated with an acceptable safety profile 150 µg 250 µg 400 µg 650 µg Somnolence 0 1 1 1 Dysaesthesia 0 2 0 0 Disturbance in attention 0 1 0 0 Memory Impairment 0 0 1 0 Dry mouth 0 0 2 1 Diarrhea 0 1 0 0 Dyspepsia 0 1 0 0 Fatigue 0 0 0 1 Overdose 0 1 0 0 11 CAReS Phase 1/2 Safety Data presented by Professor Barry J. A. Laird, Professor of Palliative Medicine, University of Oslo and Oslo University Hospital/Radium Hospital, at the 8th Cancer Cachexia Conference, September 27, 2025. CAReS = Cancer Appetite Recovery Study
Page 12
NASDAQ: ARTLNasdaq:ARTL ART27.13 CAReS Phase 2 Results CAReS inclusion criteria required a documented >5% weight loss during the prior 6 months 12 Weight changes pre-, during and post-treatment Data presented by Professor Barry J. A. Laird, Professor of Palliative Medicine, University of Oslo and Oslo University Hospital/Radium Hospital, at the 8th Cancer Cachexia Conference, September 27, 2025. CAReS = Cancer Appetite Recovery Study ART27.13 dosing period up to 12 weeks (90 days) Duration of safety follow up up to 4 weeks (30 days)
Page 13
NASDAQ: ARTLNasdaq:ARTL ART27.13 CAReS Phase 2 Results Change in Activity Efficacy versus placebo in lean body mass, weight gain, activity, and well-tolerated up to 1300 μg per day 13 At end of treatment there was an average 6% increase in weight in patients who escalated to 1300 ug and a 5% decrease in patients who received placebo Change in Weight Activity data captured by MotionWatch showed an increase in total activity for patients on active treatment compared to those on placebo Data presented by Professor Barry J. A. Laird, Professor of Palliative Medicine, University of Oslo and Oslo University Hospital/Radium Hospital, at the 8th Cancer Cachexia Conference, September 27, 2025. CAReS = Cancer Appetite Recovery Study
Page 14
ART26.12 Fatty Acid Binding Protein 5 (FABP5) Inhibitor
Page 15
NASDAQ: ARTL Nasdaq:ARTL FABP Inhibitor Platform Cancer Pain and Inflammation Anxiety Disorders Dermatology • Generalized Anxiety Disorder • Depression • PTSD • Psoriasis • Osteoarthritis • Chemotherapy Induced Peripheral Neuropathy (CIPN) • Diabetic neuropathy • Cancer bone pain • Prostate cancer • Breast cancer • Colon cancer • Various other cancers Fatty Acid Binding Proteins are a validated target with potential in multiple therapeutic areas. Artelo has a worldwide exclusive license from Stony Brook University, NY for multiple generations of FABP inhibitors. 15
Page 16
NASDAQ: ARTL Nasdaq:ARTL ART26.12 Our Lead FABP5 Inhibitor Target Indication: Chemotherapy-Induced Peripheral Neuropathy (CIPN) Fatty Acid Binding Protein 5 (FABP5) Inhibitor offers potential as a first-in-class, non-opioid, non- psychoactive approach to pain and inflammation CIPN affects up to 40% of all treated cancer patients* and is marked by extreme nerve pain causing delays, disruption or discontinuation of essential cancer treatment with no currently available FDA approved therapy 16*Staff NP, et. al., Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol. 2017;81(6):772-781
Page 17
NASDAQ: ARTL Nasdaq:ARTL ART26.12 administered as a prophylactic dose of 25 mg/kg orally twice daily in multiple CIPN animal studies • Significantly reversed cold allodynia latencies in oxaliplatin induced CIPN by day 151 • Reduced mechanical and cold allodynia associated with paclitaxel induced CIPN by day 152 Values are presented as mean ± s.e.m. (n=9-11). Study was performed in male Sprague Dawley Rats. Oxaliplatin CIPN Coldplate Prevention Study1 1 https://www.jpain.org/article/S1526-5900(24)00345-6/fulltext 2 The Effects of the FABP5 Inhibitor ART26.12 in Paclitaxel-Induced Neuropathy S.E. O’Sullivan, A. Pereira, M. Kaczocha, I. Ojima and A. Yates presented at International Cannabinoid Research Society annual meeting 2023 Evidence from five animal studies in peripheral neuropathy with ART26.12 supports Artelo’s development strategy for the FABP5 inhibitor as a potential preventative therapeutic for CIPN ART26.12 Strong Pre-Clinical Evidence from Multiple Studies Baseline Day 5/6 Day 15 0 20 40 60 80 100 Coldplate Latency (s) Vehicle n=9 ART26.12 (10mg/kg) n=10 ART26.12 (25mg/kg) n=10 0.051 # * Baseline Day 5/6 Day 15 0 20 40 60 80 100 Coldplate Latency (s) Vehicle n=9 ART26.12 (10mg/kg) n=10 ART26.12 (25mg/kg) n=10 0.051 # * 17
Page 18
NASDAQ: ARTL Nasdaq:ARTL Clinical data from completed SAD and preliminary Food Effect study demonstrated: • Excellent Safety Profile: All adverse events (AEs) were mild, transient, and self-resolving and believed by medical staff not related to study drug • Predictable Pharmacokinetics: Plasma analysis confirmed dose-dependent linear absorption • Therapeutic Window: A wide safety margin was observed between estimated therapeutic plasma concentrations and the highest exposure levels achieved. • Potential for fed or fasted dosing The Phase 1 Single Ascending Dose (SAD) & Food Effect (FE) study was designed to assess the safety, tolerability, and pharmacokinetics of ART26.12 in healthy volunteers. The SAD/FE study enrolled 55 subjects. ART26.12 Phase 1 Study Results 18 SAD Study Endpoints • To evaluate the safety and tolerability of QD ascending oral doses of ART26.12 versus placebo in fasted healthy adult volunteers • ART26.12 safety profile understood on single dosing • DLT defined on single dosing • To evaluate the PK and PD profile of oral doses of ART26.12 • Plasma and urine PK • Lipidomic and proteomic biomarkers Cohort 1 - 50mg Cohort 2 - 150mg Cohort 6 - 1050mg Cohort 5 - 900mg Cohort 4 - 600mg Cohort 3 - 300mg Dose escalation decisions in the SAD based on at least 6 dosed volunteers (6 active, 2 placebo in total in each cohort). Study Design Food Effect investigation evaluated 6 participants each receiving three doses.
Page 19
ART12.11 CBD:TMP Cocrystal
Page 20
NASDAQ: ARTL Nasdaq:ARTL Target indication: Anxiety/Depression ART12.11 CBD:TMP Cocrystal Anxiety and depression affects about 20% of adults in the US* and is often characterized by feelings of sadness, hopelessness, worry, or dread Proprietary CBD:TMP Cocrystal is a combination drug candidate with improved physical properties, pharmacokinetics, and pharmacology CBD=cannabidiol ; TMP=tetramethylpyrazine 20* National Center for Health Statistics. (2024). Report No. 213. Centers for Disease Control and Prevention. https://www.cdc.gov/nchs/data/nhsr/nhsr213.pdf
Page 21
NASDAQ: ARTL Nasdaq:ARTL ART12.11 Multiple Competitive Advantages CBD:TMP cocrystal solved inherent challenges with CBD in accordance with FDA Guidance DRUG CBD CBD:TMP COCRYSTAL TMP COFORMER Physical Properties Pharmacodynamics Patent EstatePharmacokinetics Delivers higher plasma levels of CBD and its major metabolite CBD-7COOH compared to CBD alone and less impact of food effect than CBD alone Composition of Matter & Methods of Use issued in US through December 2038 and National Phase approvals ongoing worldwide Strong anxiolytic, anti- depressive, and pro-social effects while protecting spatial and short-term memory ART12.11 Developed as an oral solid with improved melting point, solubility, and dissolution compared to CBD alone 21
Page 22
NASDAQ: ARTL Nasdaq:ARTL Clinical Behavior Behavioral Test ART12.11 (3.5 mg/kg CBD + 1.5 mg/kg TMP orally dosed) CBD-alone (10 mg/kg orally dosed) Anxiety Elevated plus maze Anxiolytic No effectLight-dark chamber Open field test Depression Sucrose preference Anti-depressive (reversed stress effect) No effect Forced swim test Sociability Social motivation Pro-social (reversed stress effect) No effect Social discrimination Cognition Novel-object recognition Protected memory (reversed stress effect) No effect or impaired spatial memorySpontaneous alternation ART12.11 Promising Anxiety and Depression Data Superior preclinical efficacy observed in stress-induced anxiety model compared to CBD-alone X X Positive Effect No Effect Negative Effect X X X X Data presented at Society for Neuroscience (SfN) 2023 and available on Artelo’s website (artelobio.com). 22
Page 23
NASDAQ: ARTLNasdaq:ARTL Gregory Gorgas President & CEO, Director Biogen IDEC, Chiron, Cetus, Upjohn, MAST Steven D. Reich, MD Chief Medical Officer Pfizer, Ligand, Biogen, PAREXEL Andrew Yates, PhD Chief Scientific Officer UK Pharmacist, AstraZeneca, Bristol Myers Saoirse O’Sullivan, PhD VP, Translational Science Prof., University of Nottingham, UK Mark Spring, CPA Chief Financial Officer LENZ, Hyperion, Prometheus, Caremark, Baxter 23 Proven track record of value creation for shareholders MANAGEMENT TEAM Martin Kaczocha, PhD Assistant Professor of Anesthesiology and Biochemistry and Cell Biology, Stony Brook University, New York, US Steven Laviolette, PhD Professor, University of Western Ontario, Canada Iwoa Ojima, PhD Distinguished Professor, Chemistry, and Director, Institute of Chemical Biology and Drug Discovery, Stony Brook University, New York, US Richard K. Porter, PhD Associate Professor, Biochemistry & Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland Connie Matsui Chair of the Board Wells Fargo, Biogen IDEC, Sutro Biopharma, Halozyme Steven Kelly Compensation Committee Chair Carisma, Theracrine, Amgen, IDEC, Sanofi Douglas Blayney, MD Nominating & Governance Committee Chair ASCO President, Stanford Cancer Center, University of Michigan, NCI R. Martin Emanuele, PhD DuPont, Avanir, DaVita, MAST, Visgenx Greg Reyes, MD, PhD Celgene, Biogen IDEC, Pfizer, Schering- Plough Research Institute Tamara A. Favorito Audit Committee Chair Immunic, HemaQuest, Favrille, Agouron, Deloitte & Touche, PricewaterhouseCoopers BOARD OF DIRECTORS SCIENTIFIC COLLABORATORS Leadership
Page 24
NASDAQ: ARTLNasdaq:ARTL Capitalization (as of 10/31/2025) Common Shares Outstanding 2,010,038 Shares issuable upon conversion of convertible notes 219,091 Warrants (WAEP $5.31) 1,430,766 Options (WAEP $10.94) 230,342 Total 3,890,237 Cash, Cash Equivalents, and Marketable Securities (as of 9/30/2025): $1.7M Convertible Debt (as of 9/30/2025; maturity 4/28/2026): Fully diluted ownership of Officers/Directors (as of 10/31/2025): $0.9M 5% WAEP = Weighted Average Exercise Price 24 Company Capitalization
Page 25
NASDAQ: ARTLNasdaq:ARTL 25 NOVEL SCIENCE PORTFOLIO PROVEN LEADERSHIP ROBUST PATENT ESTATE NEAR-TERM MILESTONES BILLION DOLLAR MARKETS • ART27.13 Benzimidazole derivative in Phase 2 • ART26.12 FABP5 inhibitor in Phase 1 • ART12.11 CBD:TMP cocrystal in late preclinical 38 patents issued 51 patents pending (includes owned, licensed, and partnered) Composition of matter and broad method claims ensure strong prospects for meaningful worldwide market exclusivity • CIPN $2B • Cancer anorexia $3B+ • Prostate cancer $13B • Breast cancer $33B • Psoriasis $31B • Anxiety $13B • PTSD $13B Experienced team of biopharmaceutical executives, drug developers, and top tier researchers Proven track records in developing and commercializing high-impact federally regulated therapeutics $B • 1H25 ART26.12 SAD/FE (single ascending dose & food effect) • 2H25 ART27.13 Interim Phase 2 CAReS Data • 1H26 ART26.12 MAD (multiple ascending dose) • 2H26 ART12.11 Phase 1 Artelo Investment Opportunity Summary
Page 26
Nasdaq:ARTL artelobio.com artelo-biosciences-inc artelo-biosciences-inc @ArteloBio @ArteloBio INVESTOR RELATIONS (212) 671-1020 ARTL@crescendo-ir.com